Journal
GENES
Volume 5, Issue 3, Pages 748-766Publisher
MDPI
DOI: 10.3390/genes5030748
Keywords
personalized medicine; clinical genomics; regulation; quality assurance
Categories
Funding
- GlaxoSmithKline
Ask authors/readers for more resources
The tremendous increase in DNA sequencing capacity arising from the commercialization of next generation instruments has opened the door to innumerable routes of investigation in basic and translational medical science. It enables very large data sets to be gathered, whose interpretation and conversion into useful knowledge is only beginning. A challenge for modern healthcare systems and academic medical centers is to apply these new methods for the diagnosis of disease and the management of patient care without unnecessary delay, but also with appropriate evaluation of the quality of data and interpretation, as well as the clinical value of the insights gained. Most critically, the standards applied for evaluating these new laboratory data and ensuring that the results and their significance are clearly communicated to patients and their caregivers should be at least as rigorous as those applied to other kinds of medical tests. Here, we present an overview of conceptual and practical issues to be considered in planning for the integration of genomic methods or, in principle, any other type of omics testing into clinical care.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available